Clinical trial • Phase III • Ophthalmology
Clinical trial in Retinal degenerative diseases | Stargardt disease | Dry age-related macular degeneration | Retinitis pigmentosa
Phase III trial for Retinal degenerative diseases | Stargardt disease | Dry age-related macular degeneration | Retinitis pigmentosa. 10 participants.
Overview
- Trial Therapeutic Area
- Ophthalmology
- Trial Disease
- Retinal degenerative diseases | Stargardt disease | Dry age-related macular degeneration | Retinitis pigmentosa
- Trial Stage
- Phase III
- Drug Modality
- Cell therapy
Key dates
- Initial CTIS Submission Date
- 10-12-2025
- First CTIS Authorization Date
- 28-04-2026
Recruitment
- Planned Sample Size
- 10
- Recruitment Window Months
- 24
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 10
Czechia
- Earliest CTIS Part Ii Submission Date
- 01-02-2026
- Latest Decision Or Authorization Date
- 28-04-2026
- Processing Time Days
- 86
- Number Of Sites
- 1
- Number Of Participants
- 10
Sites
- Site Name
- GEMINI ocni klinika a.s.
- Department Name
- Vitreoretinal Center of the GEMINI eye clinic
- Contact Person Name
- Jaroslav Polišenský
- Contact Person Email
- polisensky@gemini.cz
- Number Of Participants
- 10
Sponsor
Primary sponsor
- Full Name
- Bioinova a.s.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Czechia
Related trials
Other published trials that may interest you.